Ignite Creation Date:
2025-12-25 @ 4:03 AM
Ignite Modification Date:
2026-01-13 @ 5:21 PM
Study NCT ID:
NCT03523702
Status:
COMPLETED
Last Update Posted:
2024-12-03
First Post:
2018-05-02
Is NOT Gene Therapy:
True
Has Adverse Events:
True
Brief Title:
The Selective Personalized Radio-Immunotherapy for Locally Advanced NSCLC Trial
Sponsor:
Albert Einstein College of Medicine
Organization:
Study Overview
Official Title:
The Selective Personalized Radio-Immunotherapy for Locally Advanced NSCLC Trial (SPRINT)
Status:
COMPLETED
Status Verified Date:
2024-11
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
SPRINT
Brief Summary:
The goal of this study is to explore if, for locally advanced non-small cell lung cancer patients whose tumors have high levels of PD-L1 (a marker associated with benefits from immunotherapy), a combination of immunotherapy and a personalized 4-week radiotherapy course could be more effective than standard treatment, which is a combination of chemotherapy and radiotherapy.
Detailed Description:
This is a Phase II trial evaluating the efficacy and safety of sequential pembrolizumab (200 mg every three weeks) and accelerated, dose-painted radiotherapy for patients with locally advanced NSCLC with PD-L1 expression ≥ 50%. Patients with PD-L1 expression \< 50% will be treated with concurrent chemoradiotherapy as part of standard of care.
Study Oversight
Has Oversight DMC:
True
Is a FDA Regulated Drug?:
True
Is a FDA Regulated Device?:
False
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
True
Is an FDA AA801 Violation?: